Camostat

From Infogalactic: the planetary knowledge core
Jump to: navigation, search
Camostat
File:Camostat.svg
Systematic (IUPAC) name
N,N-dimethylcarbamoylmethyl 4-(4-guanidinobenzoyloxy)phenylacetate
Clinical data
AHFS/Drugs.com International Drug Names
Legal status
  • ℞ (Prescription only)
Routes of
administration		 Oral
Identifiers
CAS Number 59721-29-8 YesY (mesylate)
ATC code B02AB04 (WHO)
PubChem CID: 2536
IUPHAR/BPS 6432
ChemSpider 2440 YesY
UNII 0FD207WKDU YesY
ChEMBL CHEMBL590799 YesY
Chemical data
Formula C20H22N4O5
Molecular mass 398.41 g/mol
  • CN(C)C(=O)COC(=O)CC1=CC=C(C=C1)OC(=O)C2=CC=C(C=C2)N=C(N)N
  • InChI=1S/C20H22N4O5/c1-24(2)17(25)12-28-18(26)11-13-3-9-16(10-4-13)29-19(27)14-5-7-15(8-6-14)23-20(21)22/h3-10H,11-12H2,1-2H3,(H4,21,22,23) YesY
  • Key:XASIMHXSUQUHLV-UHFFFAOYSA-N YesY
  (verify)

Camostat (INN) or FOY-305 is a serine protease inhibitor. Serine protease enzymes have a variety of functions in the body, and so camostat has a diverse range of uses. It is used in the treatment of some forms of cancer and is also effective against some viral infections, as well as inhibiting fibrosis in liver or kidney disease or pancreatitis.[1][2][3][4][5][6]

References

<templatestyles src="Reflist/styles.css" />

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />
  • Lua error in package.lua at line 80: module 'strict' not found.
  • Lua error in package.lua at line 80: module 'strict' not found.

<templatestyles src="Asbox/styles.css"></templatestyles>

Stub icon

This drug article relating to the blood and blood forming organs is a stub. You can help Wikipedia by expanding it.
  1. ↑ Okuno M, Kojima S, Akita K, Matsushima-Nishiwaki R, Adachi S, Sano T, Takano Y, Takai K, Obora A, Yasuda I, Shiratori Y, Okano Y, Shimada J, Suzuki Y, Muto Y, Moriwaki Y. Retinoids in liver fibrosis and cancer. Front Biosci. 2002 Jan 1;7:d204-18. PMID 11779708
  2. ↑ Motoo Y. Antiproteases in the treatment of chronic pancreatitis. JOP. 2007 Jul 9;8(4 Suppl):533-7. PMID 17625311
  3. ↑ Hsieh HP, Hsu JT. Strategies of development of antiviral agents directed against influenza virus replication. Curr Pharm Des. 2007;13(34):3531-42. PMID 18220789
  4. ↑ Kitamura K, Tomita K. Proteolytic activation of the epithelial sodium channel and therapeutic application of a serine protease inhibitor for the treatment of salt-sensitive hypertension. Clin Exp Nephrol. 2012 Feb;16(1):44-8. doi: 10.1007/s10157-011-0506-1 PMID 22038264
  5. ↑ Zhou Y, Vedantham P, Lu K, Agudelo J, Carrion R Jr, Nunneley JW, Barnard D, Pöhlmann S, McKerrow JH, Renslo AR, Simmons G. Protease inhibitors targeting coronavirus and filovirus entry. Antiviral Res. 2015 Apr;116:76-84. doi: 10.1016/j.antiviral.2015.01.011 PMID 25666761
  6. ↑ Ueda M, Uchimura K, Narita Y, Miyasato Y, Mizumoto T, Morinaga J, Hayata M, Kakizoe Y, Adachi M, Miyoshi T, Shiraishi N, Kadowaki D, Sakai Y, Mukoyama M, Kitamura K. The serine protease inhibitor camostat mesilate attenuates the progression of chronic kidney disease through its antioxidant effects. Nephron. 2015;129(3):223-32. doi: 10.1159/000375308 PMID 25766432
Retrieved from "https://infogalactic.com/w/index.php?title=Camostat&oldid=5290436"